Jump to Main Content
- Campbell, R. Keith; White, John R.
- TheDiabetes educator 2008 v.34 no.3 pp. 518-534
- alpha-glucosidase; antagonists; bile acids; blood pressure; body weight; cannabinoid receptors; clinical trials; dipeptidyl-peptidase IV; enzyme inhibitors; glucagon-like peptide 1; glycemic control; glycemic effect; glycosylation; guidelines; hemoglobin; hyperlipidemia; hypertension; insulin; insulin resistance; islets of Langerhans; kidney diseases; lipid composition; metformin; noninsulin-dependent diabetes mellitus; peripheral nervous system diseases; retinal diseases; secretin; sulfonylureas; therapeutics; thiazolidinediones
- ... The goal of antidiabetes therapy is to reduce glycosylated hemoglobin (HbA1c) levels to prevent or minimize the microvascular complications associated with this disease, such as retinopathy, nephropathy, and neuropathy. Glycemic control, defined by the American Diabetes Association (ADA) as HbA1c < 7.0%, is often difficult to achieve despite current treatments, including oral antidiabetes agents, ...